Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1

Maria-Victoria Mateos, Tamas Masszi, Norbert Grzasko, Markus Hansson, Irwindeep Sandhu, Ludek Pour, Luísa Viterbo, Sharon R. Jackson, Anne-Marie Stoppa, Peter Gimsing, Mehdi Hamadani, Gabriela Borsaru, Deborah Berg, Jianchang Lin, Alessandra Di Bacco, Helgi van de Velde, Paul G. Richardson, and Philippe Moreau


Contributions: Study conception and design – DB, JL, HvdV, ADB, PGR, PM Collection and assembly of data – M-VM, TM, NG, MH, IS, LP, LV, SRJ, A-MS, PG, MH, GM, PGR, PM Data analysis and interpretation – M-VM, DB, JL, ADB, HvdV, PGR, PM, Provision of study materials or patients – M-VM, TM, NG, MH, IS, LP, LV, SRJ, A-MS, PG, MH, GM, PGR, PM Drafting or revising the manuscript – M-VM, DB, HvdV, and AdB drafted the manuscript, and all authors contributed to revising the manuscript Review and approval of the final version of the manuscript – All authors